Expression and Significance of LncRNA RP11-513G11.1 in Peripheral Blood of Patients with Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2019.05.024
- Author:
Jun-Ling TANG
1
;
Xiao-Ming LI
2
;
Li ZHANG
3
Author Information
1. Department of Hematology, Affiliated Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province, China.
2. Department of Hematology, Affiliated Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province, China,E-mail: lixiaoming11@163.com.
3. Department of Oral and Maxillofacial Surgery, Stomatological Hospital Affiliated to Southwest Medical University,Luzhou 646000,Sichuan Province, China,E-mail: 71587374@qq.com.
- Publication Type:Journal Article
- MeSH:
B-Lymphocytes;
Germinal Center;
Humans;
Lymphoma, Large B-Cell, Diffuse;
genetics;
Prognosis;
RNA, Long Noncoding;
genetics
- From:
Journal of Experimental Hematology
2019;27(5):1515-1521
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression and significance of LncRNA RP11-513G11.1 in peripheral blood of patients with diffuse large B-cell lymphoma (DLBCL), and to analyze its correlation with clinicopathological features and prognosis of patients.
METHODS:The serum samples of 93 patients with DLBCL(DLBCL group) and 62 normal persons (control group) were collected from the Department of Hematology, Southwest Medical University. The expression of RP11-513G11.1 in serum samples was detected by real-time fluorescence quantitative PCR, the relationship between the RP11-513G11.1 expression with clinicopathological characteristics and prognosis was analyzed.
RESULTS:Compared with normal control group, the expression of RP11-513G11.1 significantly increased in DLBCL patients (P<0.001). The expression of RP11-513G11.1 not related with the age, sex, course of treatment and germinal center B-cell-like lymphoma(GCB) subtypes of the patients, but it related with the diameter of tumor,Ann Arbor stage,B symptoms,chemosensitivity and the international prognostic index(IPI) (P<0.05). The progression-free survival time and overall survival time of patients, whom with high expression of RP11-513G11.1 were significantly shorter than those of RP11-513G11.1 low expression（P<0.001）. The median progression-free survival time and overall survival time of chemotherapy-sensitive patients were significantly longer than those of chemotherapy-resistant patients (P<0.001). Univariate analysis and multivariate Cox regression analysis showed that Ann Arbor stage, RP11-513G11.1 expression, IPI and chemosensitivity were also the independent factors affecting the prognosis of DLBCL patients（P<0.05）.
CONCLUSION:RP11-513G11.1 is highly expressed in patients with DLBCL, which is related with the prognosis of DLBCL patients.
